# A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

> **NCT05513703** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 9 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Telisotuzumab Vedotin

## Key facts

- **NCT ID:** NCT05513703
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-21
- **Primary completion:** 2024-10-28
- **Final completion:** 2024-10-28
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05513703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05513703, "A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05513703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*